



AstraZeneca
1800 Concord Pike
Wilmington, Delaware 19803-2910
T: (800) 456-3669
astrazeneca.com

November 13, 2025

AstraZeneca Notice Regarding Refunds to 340B Covered Entities

AstraZeneca Pharmaceuticals LP (“AstraZeneca”) has recalculated the 340B Ceiling Price for select National Drug Codes (NDCs) covering the period from October 1, 2020, through September 30, 2024. As a result of the recalculated 340B Ceiling Price, AstraZeneca has determined a refund may be owed to 340B Covered Entities that purchased the below products during the sales period. AstraZeneca is not seeking reimbursement or repayment where 340B Covered Entities paid a lower price than the recalculated 340B ceiling price for the indicated time period, and any such amounts will not be used as offsets in determining the aggregate amount of any refund due.

The table below identifies the product, NDC, and sales period that were subject to a refund. The recalculated Ceiling Prices are the result of revised pricing data submitted to the Centers for Medicare & Medicaid Services.

Product Description	NDC 11	340B Sales Period
BEVESPI AERO HO IHL 7.2/4.8MCG 1X28D US	00310460039	4Q20
BEVESPI AERO IHL 9.0/4.8MCG 1X120D US	00310460012	4Q20
MOVANTIK 25MG 10X10 HUD BLISTER	00310197039	4Q20
MOVANTIK 25MG 30CT RETAIL BOTTLE	00310197030	4Q20
NEXIUM CAPSULE 40MG 1000CT BOTTLE	00186504082	4Q20
NEXIUM CAPSULE 40MG 30CT BOTTLE	00186504031	4Q20
NEXIUM CAPSULE 40MG 90CT BOTTLE	00186504054	4Q20
NEXIUM ORAL SUSPENSION 10MG 30CT RETAIL	00186401001	4Q20
NEXIUM CAPSULE 40MG 90CT BOTTLE	00186504054	1Q21
NEXIUM CAPSULE 20MG 90CT BOTTLE	00186502054	1Q21
NEXIUM CAPSULE 20MG 30CT BOTTLE	00186502031	1Q21
NEXIUM CAPSULE 40MG 30CT BOTTLE	00186504031	1Q21
NEXIUM GRA 5MG SHT 1X30 EA US	00186405001	1Q21
BEVESPI AERO HO IHL 7.2/4.8MCG 1X28D US	00310460039	2Q21
BEVESPI AERO IHL 9.0/4.8MCG 1X120D US	00310460012	2Q21

NEXIUM CAPSULE 20MG 30CT BOTTLE	00186502031	2Q21
NEXIUM CAPSULE 20MG 90CT BOTTLE	00186502054	2Q21
NEXIUM CAPSULE 40MG 30CT BOTTLE	00186504031	2Q21
NEXIUM CAPSULE 40MG 90CT BOTTLE	00186504054	2Q21
NEXIUM GRA 2.5MG SHT 1X30 EA US	00186402501	2Q21
NEXIUM GRA 5MG SHT 1X30 EA US	00186405001	2Q21
NEXIUM ORAL SUSPENSION 10MG 30CT RETAIL	00186401001	2Q21
BEVESPI AERO IHL 9.0/4.8MCG 1X120D US	00310460012	3Q21
BRILINTA 60MG 60CT RETAIL BOTTLE	00186077660	3Q21
BRILINTA 90MG TABLET 100CT HUD	00186077739	3Q21
BRILINTA 90MG TABLET 60CT RETAIL BOTTLE	00186077760	3Q21
BREZTRI 160/9.0/4.8MCG PMDI 1X120D US	00310461612	2Q22
BREZTRI 160/9.0/4.8MCG PMDI 1X28D US	00310461639	2Q22
BRILINTA 90MG TABLET 100CT HUD	00186077739	3Q22
BRILINTA 90MG TABLET 60CT RETAIL BOTTLE	00186077760	3Q22
NEXIUM CAPSULE 40MG 30CT BOTTLE	00186504031	3Q22
NEXIUM CAPSULE 40MG 90CT BOTTLE	00186504054	3Q22
AIRSUPRA 90/80MCG PMDI 120D US	00310908012	4Q23
AIRSUPRA 90/80MCG PMDI 120D US	00310908012	1Q24
FARXIGA TAB 5MG BT 1X90 EA US	00310620590	2Q24
FARXIGA TAB 10MG BT 1X90 EA US	00310621090	2Q24
FARXIGA TAB 5MG BT 1X90 EA US	00310620590	3Q24
FARXIGA TAB 10MG BT 1X90 EA US	00310621090	3Q24

AstraZeneca has communicated and facilitated refund adjustments through the wholesalers responsible for submitting the original sales on behalf of the 340B Covered Entities. Should 340B Covered Entities have concerns regarding the receipt or accuracy of your adjustment, please contact your respective wholesaler for further assistance.

AstraZeneca has asked the Health Resources and Services Administration (HRSA) to post this Notice on HRSA's public website to ensure transparency to 340B Covered Entities. Please direct any questions and/or requests for additional information to AstraZeneca at the following email address: 340b@astrazeneca.com.